Geron (FRA:GON) Tariff Resilience Score: 9/10 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GON Geron Corp FRA:GON
39 GF Score
Price €1.18
GF Value €5.62
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Geron Tariff Resilience Score?

Geron FRA:GON -2.83% 39 Tariff Resilience Score is 9 as of Jul. 16, 2026. GuruFocus rates FRA:GON with a GF Score™ of 39/100 and a GF Value™ of €5.62 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,370 Biotechnology companies, Geron ranks better than 99.93% on this metric.

Geron has the Tariff Resilience Score of 9, which implies that the company might have Highly Resilient.

Geron has Geron Corp operates in biotechnology with minimal exposure to tariffs. Its supply chain is not heavily reliant on international trade, and it benefits from industry-specific exemptions. Historical tariff changes have had negligible effects.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Geron might have Highly Resilient.

Geron  (FRA:GON) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Geron Tariff Resilience Score Related Terms

FRA:GON vs SPRY, PHAT, DSGN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Geron's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Geron Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geron's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Geron's Tariff Resilience Score falls into.


FRA:GON
39GF Score
Geron Corp FRA:GON
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 9 mean?
Geron (FRA:GON) has a Tariff Resilience Score of 9 as of Jul. 16, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Geron ranks #1 out of 1370 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Geron's Tariff Resilience Score too high?
Geron's current Tariff Resilience Score is 9. The Biotechnology industry median Tariff Resilience Score is 4.00. Geron's value of 9 is 125% above this industry median. Based on the distribution chart, Geron ranks #1 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Geron has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's Tariff Resilience Score compare to SPRY and PHAT?
According to the Biotechnology industry distribution chart, Geron ranks #1 out of 1370 companies for Tariff Resilience Score. This places Geron in the top 0% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Geron's value of 9 is 125% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Geron's current Tariff Resilience Score of 9 is 125% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geron's current Tariff Resilience Score is 9. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (FRA:GON) is currently considered Possible Value Trap. The stock's GF Value™ is €5.62, compared to a current price of €1.18 — trading 78.9% below its estimated fair value. The current Tariff Resilience Score is 9 and 125% above the Biotechnology industry median of 4.00. Geron's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Geron (FRA:GON), the current Tariff Resilience Score is 9 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Geron (FRA:GON) Overvalued in 2026?

Based on GuruFocus' analysis, Geron stock appears to be undervalued. The current stock price of €1.18 is trading 78.9% below its estimated GF Value™ of €5.62. GuruFocus considers Geron to be Possible Value Trap.

Key valuation signals for FRA:GON:

  • Tariff Resilience Score: 9
  • GF Value™: €5.62 vs. price of €1.18 (78.9% below fair value)
  • GF Score™: 39/100 with 4 warning signs
  • Industry Position: 125% above the Biotechnology median (#1 of 1370)

No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Geron Business Description

Address 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
39GF Score

Get the complete analysis for FRA:GON

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.18
Price
€5.62
GF Value